“We significantly raised the profile of Alterity and ATH434 at the MDS Congress with several data presentations ... in efficacy endpoints to optimize design of a definitive Phase 3 study.
Achieves 10% year-over-year revenue growth, record GAAP net income of $27.8 million and adjusted EBITDA of $43.2 millionThird-quarter GAAP ...
Tasting Table on MSN13h
The Luxury BBQ Sauce That Just Might Be Worth The SplurgeIf you only eat the best of the best, then doesn't that applies to what goes on your food, too? Skip the bargain brand for a ...
“We significantly raised the profile of Alterity and ATH434 at the MDS Congress with several data presentations ... in efficacy endpoints to optimize design of a definitive Phase 3 study.
A2 Bio shares clinical study progress and the increased diversity of participants in the BASECAMP-1 prescreening study during the SITC annual meeting.
ZME Science on MSN4d
Did China just copy SpaceX’s Starship?(LEFT) SpaceX launched its fourth Starship test flight from the company’s Starbase in Boca Chica, Texas, in June 2024; (RIGHT ...
Zacks Small Cap Research on MSN11d
OTC Markets Hosts Virtual Investor Presentation with Prashant Kohli, CEO of Grace Therapeutics (Acasti Pharma), with John Vandermosten, Senior Analyst at Zacks SCRACST Since the recording of this interview, the company has changed its name to Grace Therapeutics and is now trading under NASDAQ:GRCE. John Viglotti: Hello, and welcome to Virtual Investor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback